Package | us.nlm.vsac |
Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1078.680 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1078.680/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.680 |
Version | 20240206 |
Status | active |
Date | 2024-02-06T01:09:28-05:00 |
Name | GLP1RADMASCVD |
Title | GLP1RA DM ASCVD |
Realm | us |
Authority | hl7 |
Description | Excluded oral form of semaglutide (only Rybelsus) |
Purpose | (Clinical Focus: Medications containing GLP-RAs that have evidence for benefit in ASCVD (that is, reduction in MACE - major adverse cardiac events) per the ADA Standards of Care in Diabetes 2023),(Data Element Scope: DRUG_CLASS_MEMBERS: PHARMACOLOGIC:),(Inclusion Criteria: RxCUIs for medications containing one of the following ingredients: * dulaglutide * liraglutide * semaglutide (ONLY subcutaneous form)),(Exclusion Criteria: Excluded oral form of semaglutide) |
No resources found
CodeSystem | |
rxnorm | RxNorm |
rxnorm | RxNorm |
No narrative content found in resource